RU2013157923A - Терапия на основе модулирования иммунодоминантности - Google Patents

Терапия на основе модулирования иммунодоминантности Download PDF

Info

Publication number
RU2013157923A
RU2013157923A RU2013157923/10A RU2013157923A RU2013157923A RU 2013157923 A RU2013157923 A RU 2013157923A RU 2013157923/10 A RU2013157923/10 A RU 2013157923/10A RU 2013157923 A RU2013157923 A RU 2013157923A RU 2013157923 A RU2013157923 A RU 2013157923A
Authority
RU
Russia
Prior art keywords
patient
epitope
antigen
cell
cells
Prior art date
Application number
RU2013157923/10A
Other languages
English (en)
Inventor
Альфред Э. СЛАНЕТЦ
Original Assignee
ДЖИНЕИУС БАЙОТЕКНОЛОДЖИ ИНВЕСТМЕНТС, ЭлЭлСи
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ДЖИНЕИУС БАЙОТЕКНОЛОДЖИ ИНВЕСТМЕНТС, ЭлЭлСи filed Critical ДЖИНЕИУС БАЙОТЕКНОЛОДЖИ ИНВЕСТМЕНТС, ЭлЭлСи
Publication of RU2013157923A publication Critical patent/RU2013157923A/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/245—Herpetoviridae, e.g. herpes simplex virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A61K39/292—Serum hepatitis virus, hepatitis B virus, e.g. Australia antigen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4615—Dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
    • A61K39/4621—Cellular immunotherapy characterized by the effect or the function of the cells immunosuppressive or immunotolerising
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
    • A61K39/4622—Antigen presenting cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/46433—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464484—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464484—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
    • A61K39/464486—MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464484—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
    • A61K39/464488—NY-ESO
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/46449—Melanoma antigens
    • A61K39/464491—Melan-A/MART
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/464838—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021—Intradermal administration, e.g. through microneedle arrays, needleless injectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0613—Cells from endocrine organs
    • C12N5/0617—Thyroid and parathyroid glands
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
    • A61K2239/48—Blood cells, e.g. leukemia or lymphoma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
    • A61K2239/53—Liver
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2302—Interleukin-2 (IL-2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2304—Interleukin-4 (IL-4)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2306—Interleukin-6 (IL-6)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2307—Interleukin-7 (IL-7)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2312—Interleukin-12 (IL-12)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2315—Interleukin-15 (IL-15)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2321—Interleukin-21 (IL-21)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/999—Small molecules not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/11—Coculture with; Conditioned medium produced by blood or immune system cells
    • C12N2502/1121—Dendritic cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/11—Coculture with; Conditioned medium produced by blood or immune system cells
    • C12N2502/1157—Monocytes, macrophages
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16211—Lymphocryptovirus, e.g. human herpesvirus 4, Epstein-Barr Virus
    • C12N2710/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10171—Demonstrated in vivo effect

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Mycology (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Communicable Diseases (AREA)
  • Rheumatology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

1. Т-клетка, способная распознавать субдоминантный антиген или эпитоп у пациента, для применения в способе изменения иерархии иммунодоминантности пациента.2. Т-клетка для применения по п. 1, где Т-клетка получена посредством:a. идентификации по меньшей мере одного субдоминантного антигена или эпитопа в образце, взятом от пациента, иb. культивирования Т-клеток, которые могут распознавать указанный субдоминантный антиген или эпитоп.3. Т-клетка для применения по п. 1 или 2, где изменение иерархии иммунодоминантности лечит/предотвращает/ослабляет инфекцию, рак, воспаление, отторжение пересаженного органа или реакцию трансплантат против хозяина у пациента.4. Применение Т-клетки, способной распознавать субдоминантный антиген или эпитоп у пациента, при получении лекарственного средства для изменения иерархии иммунодоминантности у пациента.5. Применение по п. 4, где Т-клетка получена посредством:a. идентификации по меньшей мере, одного субдоминантного антигена или эпитопа в образце, взятом от пациента, иb. культивирования Т-клетки, способной распознавать указанный субдоминантный антиген или эпитоп.6. Применение по п. 4 или 5, в котором изменение иерархии иммунодоминантности лечит/предотвращает/ослабляет инфекцию, рак, воспаление, отторжение пересаженного органа или реакцию трансплантат против хозяина у пациента.7. Популяция Т-клеток для применения при изменении иерархии иммунодоминантности у пациента, получаемая посредством идентификации, по меньшей мере, одного субдоминантного антигена или эпитопа в образце, взятом от пациента, и культивирования популяции Т-клеток, способных распознавать указанный субдоминантный ан�

Claims (19)

1. Т-клетка, способная распознавать субдоминантный антиген или эпитоп у пациента, для применения в способе изменения иерархии иммунодоминантности пациента.
2. Т-клетка для применения по п. 1, где Т-клетка получена посредством:
a. идентификации по меньшей мере одного субдоминантного антигена или эпитопа в образце, взятом от пациента, и
b. культивирования Т-клеток, которые могут распознавать указанный субдоминантный антиген или эпитоп.
3. Т-клетка для применения по п. 1 или 2, где изменение иерархии иммунодоминантности лечит/предотвращает/ослабляет инфекцию, рак, воспаление, отторжение пересаженного органа или реакцию трансплантат против хозяина у пациента.
4. Применение Т-клетки, способной распознавать субдоминантный антиген или эпитоп у пациента, при получении лекарственного средства для изменения иерархии иммунодоминантности у пациента.
5. Применение по п. 4, где Т-клетка получена посредством:
a. идентификации по меньшей мере, одного субдоминантного антигена или эпитопа в образце, взятом от пациента, и
b. культивирования Т-клетки, способной распознавать указанный субдоминантный антиген или эпитоп.
6. Применение по п. 4 или 5, в котором изменение иерархии иммунодоминантности лечит/предотвращает/ослабляет инфекцию, рак, воспаление, отторжение пересаженного органа или реакцию трансплантат против хозяина у пациента.
7. Популяция Т-клеток для применения при изменении иерархии иммунодоминантности у пациента, получаемая посредством идентификации, по меньшей мере, одного субдоминантного антигена или эпитопа в образце, взятом от пациента, и культивирования популяции Т-клеток, способных распознавать указанный субдоминантный антиген или эпитоп.
8. Популяция Т-клеток по п. 7 для применения в терапии.
9. Способ, включающий стадии:
a. идентификации доминантного антигена или эпитопа и субдоминантного антигена или эпитопа в образце, взятом от пациента, и
b. культивирования Т-клетки, способной распознавать указанный субдоминантный антиген или эпитоп; и
c. лечение пациента с помощью эффективного количества указанных Т-клеток для изменения иерархии иммунодоминантности пациента.
10. Способ, включающий стадии:
a. идентификации, по меньшей мере, одного субдоминантного антигена или эпитопа в образце, взятом от пациента;
b. культивирования Т-клетки, способной распознавать указанный субдоминантный антиген или эпитоп; и
c. лечения пациента с помощью эффективного количества указанных Т-клеток для изменения иерархии иммунодоминантности пациента.
11. Способ по п. 9 или 10, в котором указанный субдоминантный антиген или эпитоп представляет собой антигены или эпитопы, по отношению к которым клеточная или гуморальная иммунная реакция не детектируется или детектируется только на низком уровне.
12. Способ по п. 9 или 10, в котором указанный субдоминантный антиген представляет собой вирусный антиген, антиген другого возбудителя инфекции, опухолевый антиген или антиген, ассоциированный с аутоиммунной реакцией, аллергией, воспалением, отторжением пересаженных органов или реакцией трансплантат против хозяина.
13. Способ по п. 9 или 10, в котором стадия (b) дополнительно включает культивирование Т-клетки в отсутствие доминантного антигена или эпитопа.
14. Способ по п. 9 или 10, в котором стадия (b) дополнительно включает культивирование Т-клетки в присутствии или в отсутствие агентов для обогащения либо супрессорных Т-клеток, либо реактивных Т-клеток.
15. Способ по п. 9 или 10, в котором стадия (c) дополнительно включает введение эффективного количества Т-клеток посредством интрадермального введения.
16. Способ по п. 9 или 10, дополнительно включающий стадию перед стадией (c), где пациента предварительно лечат кондиционирующим агентом для уменьшения количества эндогенных Т-клеток.
17. Способ по п. 9 или 10, в котором указанная Т-клетка представляет собой супрессорную Т-клетку, и где стадия (c) дополнительно включает индуцирование толерантности пациента для лечения или предотвращения аутоиммунного заболевания, аллергии, воспаления, отторжения пересаженного органа или реакции
трансплантат против хозяина.
18. Способ по п. 9 или 10, в котором указанная Т-клетка представляет собой реактивную Т-клетку, и где стадия (c) дополнительно включает индуцирование цитотоксической иммунной реакции для лечения или предотвращения инфекции или рака.
19. Способ по п. 9 или 10, дополнительно включающий построения профиля толерантности или гуморальной или клеточной иммунной реакции на субдоминантный антиген или эпитоп для определения того, успешно ли терапия восстанавливает равновесие иммунной реакции пациента.
RU2013157923/10A 2011-05-26 2012-05-25 Терапия на основе модулирования иммунодоминантности RU2013157923A (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161490505P 2011-05-26 2011-05-26
US61/490,505 2011-05-26
PCT/US2012/039605 WO2012162620A1 (en) 2011-05-26 2012-05-25 Modulated immunodominance therapy

Publications (1)

Publication Number Publication Date
RU2013157923A true RU2013157923A (ru) 2015-07-10

Family

ID=46208182

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2013157923/10A RU2013157923A (ru) 2011-05-26 2012-05-25 Терапия на основе модулирования иммунодоминантности

Country Status (12)

Country Link
US (8) US20140099341A1 (ru)
EP (2) EP2714072A1 (ru)
JP (1) JP2014516538A (ru)
KR (2) KR20160104753A (ru)
CN (2) CN111529697A (ru)
AU (4) AU2012258603A1 (ru)
CA (1) CA2874431A1 (ru)
HK (1) HK1199404A1 (ru)
RU (1) RU2013157923A (ru)
SG (2) SG10202012534VA (ru)
TW (3) TWI774957B (ru)
WO (1) WO2012162620A1 (ru)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102592673B1 (ko) 2016-05-25 2023-10-24 더 카운실 오브 더 퀸즐랜드 인스티튜트 오브 메디컬 리서치 면역요법의 방법
MX2018013959A (es) * 2016-05-25 2019-08-22 Council Queensland Inst Medical Res Metodos para tratar enfermedad autoinmune usando celulas t alogenicas.
CN109715196A (zh) 2016-06-13 2019-05-03 转矩医疗股份有限公司 用于促进免疫细胞功能的组合物和方法
KR20190037243A (ko) * 2016-06-28 2019-04-05 지니우스 바이오테크놀로지 인코포레이티드 면역치료를 위한 티 세포 조성물
AU2018328209A1 (en) 2017-09-05 2020-04-23 Torque Therapeutics, Inc. Therapeutic protein compositions and methods of making and using the same
US11925663B2 (en) 2017-10-23 2024-03-12 Atara Biotherapeutics, Inc. Methods of managing tumor flare in adoptive immunotherapy

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE511849T1 (de) * 1996-03-11 2011-06-15 Epimmune Inc Peptide mit erhöhter bindungsaffinität für mindestens drei hla-a3-ähnliche moleküle
EP1012238A4 (en) * 1997-01-31 2003-03-05 Epimmune Inc CELLS WITH PEPTIDES OR ANTIGENS WITH PEPTIDES
CA2330678C (en) 1998-05-11 2009-04-07 Miltenyi Biotec Gmbh Method of direct selection of antigen-specific t cells
TR200100936T2 (tr) * 1998-10-05 2001-08-21 Pharmexa A/S Terapötik aşılama
EP2278023A1 (en) * 2000-04-28 2011-01-26 Mannkind Corporation Epitope cluster from Melan-A/MART-1 for the induction of anti-tumor immunogenicity
FR2812087B1 (fr) * 2000-07-21 2007-05-11 Inst Nat Sante Rech Med Procede de criblage de peptides utilisables en immunotherapie
EP1558723A4 (en) 2002-11-07 2006-02-15 Johnson & Johnson Res Pty Ltd MEANS FOR THE PREPARATION AND USE OF A POPULATION OF DISEASE-SPECIFIC CYTOTOXIC T-LYMPHOCYTES
ES2350895T3 (es) * 2004-08-19 2011-01-28 University College Cardiff Consultants Limited Preparación de células t gamma delta humanas presentadoras de antígeno y su uso en inmunoterapia.
AU2005321904B2 (en) * 2004-12-29 2012-07-12 Mannkind Corporation Methods to elicit, enhance and sustain immune responses against MHC class I-restricted epitopes, for prophylactic or therapeutic purposes
SG162817A1 (en) * 2005-06-17 2010-07-29 Mannkind Corp Methods and compositions.to elicit multivalent immune responses against dominant and subdominant epitopes, expressed on cancer cells and tumor stroma
JP2013502235A (ja) 2009-08-24 2013-01-24 ベイラー カレッジ オブ メディスン 複数の腫瘍抗原または複数のウイルスに対する特異的ｃｔｌ株の作製［関連出願の相互参照］

Also Published As

Publication number Publication date
TWI774957B (zh) 2022-08-21
US20170043000A1 (en) 2017-02-16
US20140099341A1 (en) 2014-04-10
EP4285922A1 (en) 2023-12-06
US20170101625A1 (en) 2017-04-13
US20170042998A1 (en) 2017-02-16
US20170043001A1 (en) 2017-02-16
US20170216357A1 (en) 2017-08-03
TW201934749A (zh) 2019-09-01
CN103906531A (zh) 2014-07-02
CN111529697A (zh) 2020-08-14
KR20160104753A (ko) 2016-09-05
WO2012162620A1 (en) 2012-11-29
KR20140068810A (ko) 2014-06-09
US20170042999A1 (en) 2017-02-16
TW202321442A (zh) 2023-06-01
SG10202012534VA (en) 2021-01-28
EP2714072A1 (en) 2014-04-09
AU2012258603A1 (en) 2014-01-16
US11723921B2 (en) 2023-08-15
AU2019201456A1 (en) 2019-03-21
AU2021200831A1 (en) 2021-03-04
US20240189353A1 (en) 2024-06-13
SG10201604236RA (en) 2016-07-28
AU2017203671A1 (en) 2017-06-15
TW201313902A (zh) 2013-04-01
HK1199404A1 (en) 2015-07-03
JP2014516538A (ja) 2014-07-17
CA2874431A1 (en) 2012-11-29

Similar Documents

Publication Publication Date Title
RU2013157923A (ru) Терапия на основе модулирования иммунодоминантности
NZ594892A (en) Therapeutic applications of activation of human antigen-presenting cells through dectin-1
MX351226B (es) Celulas t con memoria central anti tercera parte, metodos para producirlas y uso de las mismas en transplante y tratamiento de enfermedades.
WO2013088148A3 (en) Method of treatment employing therapeutic t cell product from mobilised donors
Garrido et al. Immunotherapy eradicates metastases with reversible defects in MHC class I expression
MX2019000022A (es) Células veto generadas a partir de linfocitos t de memoria.
RU2012127685A (ru) Устройства и способы для активной клеточной иммунотерапии рака путем применения опухолевых клеток, уничтоженных при помощи высокого гидростатического давления, и дендритных клеток
AR108552A1 (es) Materiales y métodos para determinar los regímenes óptimos de administración para agentes terapéuticos
MX2021006393A (es) Metodos para expansion ex vivo de celulas exterminadoras naturales y uso de las mismas.
GEP201706766B (en) Methods and compositions for vaccinating against staphylococcus aureus
JP2014516538A5 (ru)
CN103386123A (zh) Mek作为共刺激因子制备一种新型肿瘤疫苗的方法及应用
CN104136040A (zh) 自体癌细胞疫苗
Maeurer et al. Allogeneic hematopoietic cell transplantation for GATA2 deficiency in a patient with disseminated human papillomavirus disease
ATE492287T1 (de) Tumor-vakzine mit allogenen oder xenogenen tumorzellen
MY160857A (en) A cancer vaccine
Patel et al. HIV-Specific T CELLS Expanded from HIV+ and HIV-Naive Donors Target a Range of Viral Epitopes: Implications for a Cure Strategy after Allogeneic HSCT
Chen et al. Effect of laser immunotherapy and surgery on the treatment of mouse mammary tumors
Bruni et al. Examining the Utility of a Catalytic Antioxidant in Islet Transplantation.: Abstract# C1562
Brunner et al. Efficacy of Thiotepa-Busulfan-Cyclophosphamide (TBC) Conditioning and Autologous Transplantation As Consolidation for Systemic Non-Hodgkin Lymphoma with Synchronous CNS Involvement
Sharma Loss of Expression of the Autoimmune Regulator Protein Contributes to Autoimmune Phenotypes in GvHD and Colitis
Twombley et al. Is Vitamin D Insufficiency Common in Pediatric Kidney Transplant Patients With Rejection?: Abstract# A366
Derrick et al. Pre-Solid Organ Transplantation Vaccination Status: Opportunities Revealed!.: Abstract# A364
Fichtner et al. Donor-Specific Anti-HLA Antibodies at the Time of Kidney Transplant Biopsy Associates With Late Graft Failure in Pediatric Renal Transplant Recipients.: Abstract# A365
Li Generation of Tumor-Reactive T Cells for Cancer Immunotherapy

Legal Events

Date Code Title Description
FA92 Acknowledgement of application withdrawn (lack of supplementary materials submitted)

Effective date: 20200918

FZ9A Application not withdrawn (correction of the notice of withdrawal)

Effective date: 20210723